An antibody can deliver a protein toxin that stops a cell making proteins. These larger payloads belong to the related field of immunotoxins and need different delivery and safety studies.
DeBouganin is a modified ribosome-inactivating protein. A primary study tested trastuzumab-deBouganin conjugates and an antibody-fragment fusion protein in cells resistant to tubulin-payload conjugates. Both chemical conjugation and fusion-protein delivery were examined. These protein toxins are different from small-molecule degraders such as GSPT1 payloads and from conventional chemotherapy payloads. The cited cellular results do not establish clinical activity after antibody-drug conjugate treatment.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/